A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Clinical trial NCT03047395 · COMPLETED
Trial details
- NCT number
- NCT03047395
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-27
- Primary completion
- 2023-11-29
- Enrollment
- 2170
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.